期刊文献+

恶性肿瘤患者合并肺栓塞的临床特点 被引量:2

Clinical characteristics of pulmonary embolism with cancer
原文传递
导出
摘要 目的:探讨恶性肿瘤患者和抗癌治疗相关的肺栓塞的临床特点。方法回顾性分析2009年1月至2014年6月河南省直第三人民医院收治的伴发恶性肿瘤的肺栓塞患者的临床资料。结果本研究中84例肺栓塞患者中47例伴恶性肿瘤,平均年龄64岁。从确诊恶性肿瘤至出现肺栓塞的平均时间为5.5个月。最常见的恶性肿瘤是肺癌(23%),其次是胰胆管癌、胃癌、妇科肿瘤、乳腺癌和肝癌。最常用的化疗药为铂类。结论70%的患者在诊断为恶性肿瘤后1年内确诊出现了肺栓塞。肺癌为最常见的伴发肺栓塞的恶性肿瘤。 Objective To investigate the clinical characteristics of patients with cancer and pulmonary embolism ( PE) related to anticancer treatment .Methods We retrospectively analyzed the clinical data of patients with cancer who were diagnosed with PE from January 2009 to June 2014.Results Fourty-seven patients with cancer of the 84 patients with PE were analyzed .The median age was 64 years.The median time between the cancer diagnosis and the PE diagnosis was 5.5 months.Lung cancer was the most common cancer (23.0%) , followed by pancreatobiliary cancer , stomach canc-er, gynecological cancer , breast cancer , and hepatocellular carcinoma .Platinum-containing chemotherapeutic were com-mon.Conclusions PE was diagnosed within 1 year after the cancer diagnosis in 70% of patients .Lung cancer was the most common cancer .
出处 《中国实用医刊》 2016年第1期81-82,共2页 Chinese Journal of Practical Medicine
关键词 肺栓塞 恶性肿瘤 化疗 放疗 合并症 Pulmonary embolism Cancer Chemotherapy Radiotherapy Complication
  • 相关文献

参考文献4

二级参考文献14

  • 1Plegmasia alba dolens. In: Trousseau A, ed. Lectures on Clinical Medicine, Delivered at the Hotel-Dieu, Paris. London: New Sydenham Society, 1865; 5: 281-332.
  • 2Blom JW, Doggen CJ, Osanto S, et al. Malignanicies, protrombotic mutiations, and the risk of venous thrombosis. JAMAj 2005, 293(6): 715-722.
  • 3TorbickiA, Perrier A, Konstantinides S, et al. The task forse for the diagnosis and management of acute pulmonary embolism of the european society of cardiology. Guidelines on the diagnosis and management of acute pulmanmy embolism. Eur Heart J, 2008, 29(18): 2276-2315.
  • 4Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembohsm: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest, 2004, 126(3 Suppl): 338S-400S.
  • 5Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotheraassociated thrombosis. Blood, 2008, 111(10): 4902-4907.
  • 6Connolly GC, Khorana AA, Kuderer NM, et al. Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. ~trombosis Res, 2010, 126(2): 113-118.
  • 7Nagy Z, Horvath O, Kaidas J, at al. D-Dimer as a potential prognostic marker. Pathol Oncol Res, 2012, 18(3): 669-674.
  • 8Chuang YM, Yu CJ. Clinical characteristics and outcomes of lung cancer with pulmonary embolism. Oncology, 2009, 77(2): 100-106.
  • 9Khorana AA, Francis CW, Culakova E, et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol, 2006, 24(3): 484-490.
  • 10Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med, 2000, 160(6): 809-815.

共引文献1887

同被引文献16

引证文献2

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部